TScan Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
TCRX$0.19+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Additional · Accumulated · Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Common Stock · Non-voting Common Stock · Paid-In · Other Comprehensive · Accumulated · Stockholders’ | |||||||||
| Shares · Amount · Shares · Amount · Capital · Income · Deficit · Equity | |||||||||
| Balances at June 30, 2024 | 48,656,158 | $5 | 4,276,588 | $1 | $564,615 | $ | - | $(309,400) | $255,221 |
| Exercise of stock options | 421,378 | - | - | - | 1,230 | - | - | 1,230 | |
| Stock-based compensation expense | - | - | - | - | 2,523 | - | - | 2,523 | |
| Net loss | - | - | - | - | - | - | (29,887) | (29,887) | |
| Balances at September 30, 2024 | 49,077,536 | $5 | 4,276,588 | $1 | $568,368 | $ | - | $(339,287) | $229,087 |
| Balances at June 30, 2025 | 52,471,405 | $5 | 4,276,588 | $1 | $622,887 | $(4) | $(446,175) | 176,714 | |
| Stock-based compensation expense | - | - | - | - | 3,011 | - | - | 3,011 | |
| Net loss | - | - | - | - | - | - | (35,710) | (35,710) | |
| Unrealized gain on available-for-sale securities | - | - | - | - | - | 6 | - | 6 | |
| Balances at September 30, 2025 | 52,471,405 | $5 | 4,276,588 | $1 | $625,898 | $2 | $(481,885) | $144,021 | |
| Additional · Accumulated · Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Common Stock · Non-voting Common Stock · Paid-In · Other Comprehensive · Accumulated · Stockholders’ | |||||||||
| Shares · Amount · Shares · Amount · Capital · Income · Deficit · Equity | |||||||||
| Balances at January 1, 2024 | 43,552,941 | $4 | 4,276,588 | $1 | $398,459 | $ | - | $(247,597) | $150,867 |
| Exercise of stock options | 566,527 | - | - | - | 1,672 | - | - | 1,672 | |
| Issuance of common stock, net of offering costs | 4,958,068 | 1 | - | - | 33,130 | - | - | 33,131 | |
| Issuance of pre-funded warrants, net of offering costs | - | - | - | - | 128,272 | - | - | 128,272 | |
| Stock-based compensation expense | - | - | - | - | 6,835 | - | - | 6,835 | |
| Net loss | - | - | - | - | - | - | (91,690) | (91,690) | |
| Balances at September 30, 2024 | 49,077,536 | $5 | 4,276,588 | $1 | $568,368 | $ | - | $(339,287) | $229,087 |
| Balances at January 1, 2025 | 52,314,039 | $5 | 4,276,588 | $1 | $616,009 | $51 | $(375,096) | $240,970 | |
| Issuance of common stock under ESPP plan | 157,366 | - | - | - | 191 | - | - | 191 | |
| Stock-based compensation expense | - | - | - | - | 9,698 | - | - | 9,698 | |
| Net loss | - | - | - | - | - | - | (106,789) | (106,789) | |
| Unrealized loss on available-for-sale securities | - | - | - | - | - | (49) | - | (49) | |
| Balances at September 30, 2025 | 52,471,405 | $5 | 4,276,588 | $1 | $625,898 | $2 | $(481,885) | $144,021 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.